I can share the latest publicly available context, but I don’t have real-time access right now to browse fresh headlines. Here’s what’s generally notable about CFTR recently:
-
CFTR is the gene encoding the protein that functions as a chloride channel in epithelial cells; defects cause cystic fibrosis (CF) and a wide range of clinical presentations targeting the lungs, pancreas, and other organs. The year 2020–2025 saw major advances in CFTR modulators that improve protein folding, trafficking, or channel function, with combination therapies expanding options for different mutation classes. These advances are ongoing and driven by newer generations of modulators and trial designs to broaden access across CFTR mutations. [CFTR context summary]
-
Recent research themes include: (1) expanding modulators to cover more CFTR mutations, (2) gene-editing and gene-therapy approaches aiming for longer-term or curative effects, and (3) anti-inflammatory and supportive strategies to complement CFTR-directed therapies. These efforts reflect the field’s push toward personalized medicine for CF patients with diverse genetic backgrounds. [Research directions]
If you want, I can:
- Narrow to the very latest headlines (by date) and summarize key findings.
- Focus on a subtopic (modulator therapies, gene editing, newborn screening implications, or clinical trial outcomes) and provide a concise, up-to-date update.
- Provide a quick glossary of recent CFTR terminology and what each therapy aims to do.
Tell me which angle you’d prefer and I’ll tailor the update.
Sources
In their position statement for the new recommendations, ACMG acknowledged that these changes are necessary to improve equity and minimize bias and disparities in variant detection. “When it was originally developed, the previous variant list set the standard for CF carrier screening in the country,” lead author Joshua L. Deignan, PhD, FACMG, said in a release. “Now that our databases and technologies have evolved, it was time to raise the bar and set a new minimum standard. This new...
www.ascp.orgHow are a football match, a plug socket and a birthday cake linked to CFTR, the gene that causes cystic fibrosis? Find out by reading our ‘Research blast’ article celebrating 30 years since the gene was discovered.
www.cysticfibrosis.org.ukCLEVELAND - Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medicatio...
case.eduCystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.
www.uab.eduA Potential Breakthrough Treatment for Cystic Fibrosis Enters Clinical Trial Led by CI MED and U of Iowa Researchers
medicine.illinois.edua collaboration with the CF Foundation (CFF). This CF research program would work to find medications, called modulators, to correct defective CFTR protein. Since the start of this collaboration, Vertex has developed Kalydeko® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and … the second generation modulator, and ivacaftor (Kalydeco) named Symdeko, was approved for CF patients with two F508del mutations or with one F508del and one residual CFTR function mutation. Most recently, the...
www.med.umich.eduProfessor Tzyh-Chang Hwang Deciphers Pathogenic Protein Structure, Advancing Drug Development for Cystic Fibrosis and Diarrheal Diseases
www.nycu.edu.twThere's been advancement on cystic fibrosis, but there are still those living with the disease who get no relief from current treatments. Gene editing may help.
www.nhlbi.nih.govLARVOL VERI predictive biomarker news, CFTR (CF Transmembrane Conductance Regulator)
veri.larvol.comA new study confirms ivacaftor's impact on inflammation in people with cystic fibrosis (CF). Ivacaftor targets the defective protein that causes CF.
news.cuanschutz.edu